tag:blogger.com,1999:blog-2741672436160438708.post570448512017258143..comments2024-03-26T12:50:32.070-07:00Comments on Learning from and about cancer (chronic lymphocytic leukemia or CLL) by Dr. Brian Koffman: Ibrutinib (PCI 32765) Rapidly Improves Platelet Counts in CLL/SLL Patients and Has Minimal Effects On Platelet AggregationBrian Koffmanhttp://www.blogger.com/profile/13250684684103918493noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-2741672436160438708.post-81206208656761521912012-11-22T21:40:46.980-08:002012-11-22T21:40:46.980-08:00Be sure to look up Dr. Farooqui at ASH .. he will ...Be sure to look up Dr. Farooqui at ASH .. he will be handling two of the NIH posters. You will like him and also find him very interesting and forthcoming. All the best, LynnAnonymousnoreply@blogger.comtag:blogger.com,1999:blog-2741672436160438708.post-65254861598365989052012-11-20T08:22:24.928-08:002012-11-20T08:22:24.928-08:00Brian,
Look forward to your ASH reviews. One int...Brian,<br /><br />Look forward to your ASH reviews. One interesting abstract is that another institution (Memorial Sloan) seems to be stating a CLL MRD-negative success with engineered T-cells (with T-cell persistence also) like University of Penn last year if I am reading abstract correctly. ASH abstract at following address: <br /><br />https://ash.confex.com/ash/2012/webprogram/Paper53254.html <br /><br />Your opinion on engineered T-cell progress in CLL during your ASH reviews would be welcome because a second institution achieving success in this T-cell area with CLL would be hopeful news even if preliminary.Anonymousnoreply@blogger.com